Company profile
SCHOLAR ROCK HOLDING CORP
NASDAQ:SRRKBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (3)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| ISEMBYLD | approved | — | 0 | — |
| APITEGROMAB | phase3 | — | 6 | active |
| LINAVONKIBART | phase1 | — | 1 | no active trials |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (8)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07444294 | phase1 | recruiting | 2025-11-21 | 2026-12-17 | Scholar Rock, Inc. | A Single- and Multiple-Ascending Dose Study of SRK-439 in Healthy Adults |
| NCT07047144 | phase2 | recruiting | 2025-09-15 | 2028-11-01 | Scholar Rock, Inc. | A Study to Evaluate How Apitegromab Works in Subjects Who Are Less Than 2 Years Old and Have Spinal Muscular Atrophy |
| NCT03921528 | phase2 | completed | 2019-04-22 | 2021-01-19 | Scholar Rock, Inc. | An Active Treatment Study of SRK-015 in Patients With Type 2 or Type 3 Spinal Muscular Atrophy |
| NCT06445075 | phase2 | completed | 2024-05-21 | 2025-03-04 | Scholar Rock, Inc. | Efficacy and Safety of Apitegromab for the Treatment of Adults Who Are Overweight or Obese |
| NCT05156320 | phase3 | completed | 2022-04-14 | 2024-12-18 | Scholar Rock, Inc. | Efficacy and Safety of Apitegromab in Patients With Later-Onset Spinal Muscular Atrophy Treated With Nusinersen or Risdiplam |
FDA applications (1)
| Application | Approved | Type | Applicant | Products | ||||
|---|---|---|---|---|---|---|---|---|
| BLA 761463 | — | BLA | SCHOLAR ROCK, INC. | |||||
Loading… | ||||||||